You are here

Norethindrone, Generic Equivalent of Ortho-Micronor, Now Available

CORONA, Calif., June 2 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, announced today that it has launched JOLIVETTE™ (norethindrone tablets), a brand equivalent of the oral contraceptive Ortho-Micronor®, marketed by Ortho-McNeil Pharmaceutical, Inc. In 2002, Ortho-Micronor® had annual sales of approximately $51 million. JOLIVETTE™ is indicated for the prevention of pregnancy.

"Watson is known for having the broadest oral contraceptive portfolio in the pharmaceutical industry," said Joseph Papa, Watson's President and Chief Operating Officer. "The launch of JOLIVETTE™ marks our fourth oral contraceptive launch in 2003, bringing Watson's oral contraceptive product offerings to 15 products and 23 strengths."

More Headlines

Latest failure brings amyloid hypothesis into question
Guidance published on how to best design coverage for treatment of the smallest, most vulnerable victims of the opioid crisis
Agency plans to respond after receipt of letter of concern
Continuous nerve stimulation helps to alleviate withdrawal symptoms
Polypharmacy, including both prescription and OTC drugs, increase risk
Agent decreases the chance of infection due to chemo-induced febrile neutropenia
But some in industry disagree with the idea
Newer data and statistical methods can improve diagnosis and prescribing
A modified form of adoptive cell transfer targets mutations